论文信息 - Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. - 字舞流文

Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study.

Julie O. Culver | L. Kiemeney | M. Kloor | P. Chappuis | P. Hutter | I. Nagtegaal | D. Eccles | S. Leung | A. V. van Kessel | E. Stoffel | R. Kuiper | M. Kempers | F. Hogervorst | M. Ligtenberg | S. Syngal | H. Schackert | R. Büttner | M. van Gijn | I. Kluijt | T. Chan | M. Goossens | R. Sijmons | E. Holinski‐Feder | C. Tops | E. Verwiel | J. Culver | N. Hoogerbrugge | C. Aalfs | E. G. Gómez García | E. Oláh | J. Gille | B. V. van Nesselrooij | J. Papp | N. Rahner | L. Velsher | E. Redeker | F. Hes | C. Ockeloen | M. Morak | V. Steinke | E. Leter | R. S. van der Post | T. Graham | J. V. van Krieken | R. Niessen | D. Bunyan | M. Palomares | E. Holinski-Feder | E. García | Egbert Jw Redeker | E. G. Gómez Garcia | Frans B. L. Hogervorst | M. V. van Gijn

[1] R. Jover,et al. EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients. , 2010, The Journal of molecular diagnostics : JMD.

[2] L. Kiemeney,et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers , 2010, Journal of Medical Genetics.

[3] M. Todaro,et al. Colon cancer stem cells: promise of targeted therapy. , 2010, Gastroenterology.

[4] M. Kloor,et al. Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. , 2010, Cancer research.

[5] A. Shilatifard,et al. Histone H3 lysine 4 (H3K4) methylation in development and differentiation. , 2010, Developmental biology.

[6] Finlay Macrae,et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. , 2010, Journal of the National Cancer Institute.

[7] Jennifer L Hafterson,et al. Feasibility Study for Collection of HER2 Data by National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program Central Cancer Registries , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[8] E. Kuipers,et al. Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management , 2009, Hereditary cancer in clinical practice.

[9] Bhramar Mukherjee,et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. , 2009, Gastroenterology.

[10] S. Gruber,et al. Risk of pancreatic cancer in families with Lynch syndrome. , 2009, JAMA.

[11] H. Hollema,et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome , 2009, Genes, chromosomes & cancer.

[12] H T Lynch,et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications , 2009, Clinical genetics.

[13] H. Hollema,et al. Management of extracolonic tumours in patients with Lynch syndrome. , 2009, The Lancet. Oncology.

[14] D. Evans,et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations , 2009, Clinical genetics.

[15] Z. Szentirmay,et al. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome , 2009, Human mutation.

[16] Suet Yi Leung,et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1 , 2009, Nature Genetics.

[17] L. Kiemeney,et al. [The risk of cancer in the Netherlands]. , 2008, Nederlands tijdschrift voor geneeskunde.

[18] J. Visvader,et al. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[19] J. Kleibeuker,et al. Small-bowel cancer in Lynch syndrome: is it time for surveillance? , 2008, The Lancet. Oncology.

[20] J. Mecklin,et al. The risk of extra‐colonic, extra‐endometrial cancer in the Lynch syndrome , 2008, International journal of cancer.

[21] B. Bernstein,et al. Chromatin state maps: new technologies, new insights. , 2008, Current opinion in genetics & development.

[22] P. Møller,et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) , 2007, Journal of Medical Genetics.

[23] S. Leung,et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer , 2006, Nature Genetics.

[24] P. Møller,et al. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC) , 2005, Genes, chromosomes & cancer.

[25] Eric S. Lander,et al. Genomic Maps and Comparative Analysis of Histone Modifications in Human and Mouse , 2005, Cell.

[26] Markus Münz,et al. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation , 2004, Oncogene.

[27] P. Møller,et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. , 2004, Gastroenterology.

[28] S. Dooley,et al. Isolation and characterization of the human mismatch repair gene hMSH2 promoter region , 2004, Human Genetics.

[29] K. Maruyama,et al. Promoter analysis of the human mismatch repair gene hMSH2. , 1998, Gene.

[30] H. A. Bakker,et al. Epithelial Cell Adhesion Molecule (Ep-CAM) Modulates Cell–Cell Interactions Mediated by Classic Cadherins , 1997, The Journal of cell biology.

[31] R. Fodde,et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. , 1996, Gastroenterology.

[32] P. Levine,et al. Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. , 1985, Journal of the National Cancer Institute.